Correction to: Clinical Reviews in Allergy & Immunology
The original version of this article unfortunately contained a mistake in the first sentence of the fifth paragraph of the “Conclusion” section. The corrected text reads "Dexpramipexole, an investigational drug initially developed for the treatment of amyotrophic lateral sclerosis, has been shown to cause sustained eosinopenia". Additionally, in that same paragraph, the units used to measure eosinophil counts should read "μL-1".
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s12016-019-08775-4
Rights and permissions
About this article
Cite this article
Harish, A., Schwartz, S.A. Correction to: Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions. Clinic Rev Allerg Immunol 59, 273 (2020). https://doi.org/10.1007/s12016-020-08781-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-020-08781-x